zimmer share trade thursday follow strong print conserv
first-tim guidanc quarter better expect
manag took opportun set bar low zimmer return beat
rais cultur two disappoint year cash ep guidanc
came street in-lin think buy-sid
organ revenu growth clear compani recoveri
wont happen overnight still need complet remedi warsaw
facil hit timelin new product recaptur share competit
orthoped environ howev hit timelin right ship
next month drive multipl expans current discount
peer lead higher estim outlook continu see construct
begin view ep guidanc
conserv start point allow zimmer opportun beat
rais year fact ceo bryan hanson made clear actual
confid month ago zimmer abil hit target
resolv on-going suppli issu actual caus shortfal larg
gross margin increas cost manufactur warsaw facil
capit inventori next month gross margin remain
weigh compani work higher cost inventori plu
zimmer increas spend think street settl
mid-point rang view beatabl target
new set week fda visit disclos infract
like manag manag reiter confid suppli
recoveri long-await fda inspect warsaw facil finish
week given close proxim actual inspect manag
unabl provid much way detail around
plan attack address
mind expect street estim fall
midpoint manag guidanc factor return posit
organ growth anoth quarter declin
step-down gross margin compani work higher cost inventori
step-up oper spend reflect catchup share compens sg
increas pipelin invest
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
growth outlook begin improv next year expect street
settl even though compani remain track
resolut on-going suppli issu import rememb return
sustain market growth like push sale forc regain
confid new product transit full commerci launch gross
margin like still impact capit cost invest
pipelin still elev also expect modest increas
rang oper margin expans coupl top-lin growth
rang believ zimmer abl approach cash ep
growth roughli compar
share continu trade discount peer vs
ep remain bullish zimmer reiter overweight
rate name number reset materi like
messag tone commun manag call howev
weve highlight previous believ structur lower organ
sale growth profil exposur end-market grow vs peer
 long road recoveri ahead zimmer share deserv trade
discount med-tech peer zimmer hit manufactur resolut
timelin begin execut multipl new product launch
would expect multipl discount narrow next month
take account adjust estim price-
target reflect zimmer new outlook model sale
report flat organ cash ep look
model sale grow report organ
compani stabil back half year coupl cash ep
grow new price target valu share
cash ep discount large-cap peer multipl reflect
compani on-going turnaround effort lower end-market growth rate
invest thesi valuat risk
zimmer enter much prospect turnaround stori
differ time around new manag stori give credibl
import recogn go take time investor
see real progress made turnaround
first catalyst stori hire bryan hanson zimmer new
ceo mr hanson well known investor highli regard perform
covidien respect leader posit
right ship zimmer bring oper background disciplin
zimmer give investor confid conclus north
campu manufactur qualiti system issu plagu compani
last month potenti turnaround compani
expect hanson acceler compani invest special sale
team work reinvigor product develop enhanc execut
upcom launch see revenu growth begin recov
continu zimmer put warsaw issu behind launch multipl
new product reap earli benefit improv moral increas
invest dedic sale team
new price target valu share cash ep
discount large-cap peer multipl reflect compani on-going
turnaround effort lower end-market growth rate believ
structur lower organ sale growth profil exposur end-market grow
vs peer long road recoveri ahead zimmer share
deserv trade discount med-tech peer zimmer hit
manufactur resolut timelin begin execut multipl new product
launch would expect multipl discount narrow
risk rate price
risk includ long tail merger dis-synergi owe signific product
custom overlap distributor rep loss non-compet come
manag abil address recent qualiti issu potenti
increment cost address issu share loss knee post launch
stryker mako total knee system
summari financi
cash equival
flow oper activ
o/w chang work capit
flow invest activ
sale
flow financ activ
net chang cash
adj free cash flow firm
compani report morgan estim
note million except per-shar data fiscal year end dec o/w
analyst certif research analyst denot ac cover report certifi multipl research
analyst primarili respons report research analyst denot ac cover within document
individu certifi respect secur issuer research analyst cover research view
express report accur reflect person view subject secur issuer part
research analyst compens directli indirectli relat specif recommend view
express research analyst report korea-bas research analyst list front cover also certifi per
kofia requir analysi made good faith view reflect opinion without undu influenc
